< 1 minute read
Dec. 20, 2021

Tepotinib: a KGaA MET Kinase Inhibitor

tepotinib

oral MET kinase inhibitor approved for clinical use in NSCLC internal HTS and SBDD Clinical Cancer Research Merck KGaA

twitterlinkedinprintemail